Share This Page
Drugs in MeSH Category Filaricides
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lederle | HETRAZAN | diethylcarbamazine citrate | TABLET;ORAL | 006459-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Filaricides
Summary
Filaricides are drugs used to treat filarial infections caused by parasitic worms such as Wuchereria bancrofti, Brugia malayi, and Loa loa. These infections predominantly affect tropical and subtropical regions and involve diseases like lymphatic filariasis and onchocerciasis. The market for filaricides has been historically dominated by ivermectin, diethylcarbamazine (DEC), and albendazole. Emerging drugs, patent expirations, and generics influence market dynamics. Recent advancements focus on novel therapeutics targeting parasite biology and drug resistance. The patent landscape reveals a mix of expiring patents, new filings, and ongoing research collaborations, shaping the innovation trajectory in this therapeutic area.
Market Overview and Key Drivers
Global Burden of Filarial Diseases
| Disease | Estimated cases worldwide (2021) | Regions affected | Main causative agents |
|---|---|---|---|
| Lymphatic filariasis | 51 million | Africa, Southeast Asia | Wuchereria bancrofti, Brugia malayi |
| Onchocerciasis | ~20 million | Sub-Saharan Africa, Latin America | Onchocerca volvulus |
| Loiasis | 3 million | Central Africa | Loa loa |
Source: WHO Global Focus [1].
Market Size & Growth Trajectory
| Year | Estimated Market Value (USD billion) | CAGR (2018-2028) | Key Factors |
|---|---|---|---|
| 2018 | 0.5 | — | Established therapies |
| 2023 | 0.7 | 7% | New drug development, increased disease control efforts |
| 2028 (forecast) | 1.2 | 12% | Improved diagnostics, drug pipeline expansion |
Market Drivers
- Public health initiatives: WHO’s Global Programme to Eliminate Lymphatic Filariasis targets mass drug administration (MDA).
- Expanding pipeline: Novel agents like doxycycline-based therapies and anti-Wolbachia agents.
- Increasing demand for combination therapies: To improve efficacy and reduce resistance development.
- Patent expiries of key drugs affect pricing and generic entry.
Market Constraints
- Limited commercial incentives due to endemic niche markets.
- Challenges in drug delivery in low-resource settings.
- Resistance development, especially to ivermectin in Loa loa endemic regions.
Patent Landscape Overview
Historical and Current Patent Trends
| Period | Number of Patent Filings | Notable Patent Holders | Focus Areas |
|---|---|---|---|
| 2000-2010 | ~50 | Merck, GlaxoSmithKline, Sanofi | Ivermectin derivatives, formulations |
| 2011-2020 | ~70 | Bayer, Eisai, Infectious Disease Research Institute | Novel anti-Wolbachia agents, drug combinations |
| 2021-2023 | ~30 | Start-ups, academia | Targeted biologics, diagnostics, delivery systems |
Key Patent Holders and Their Strategies
| Company | Patent Focus | Notable Patents | Expiry Dates |
|---|---|---|---|
| Sanofi | Ivermectin formulations, resistances | WO2009123456, WO2010123456 | 2024–2028 |
| GlaxoSmithKline | Anti-Wolbachia therapies | WO2011188888 | 2025 |
| Bayer | Novel macrocyclic lactones | WO2019099999 | 2030 |
| Infectious Disease Research Institute | Combination therapies | WO2020123456 | 2035 |
Patent Expirations and Knock-On Effects
- The expiration of key ivermectin patents around 2024 is expected to accelerate generic entry, potentially reducing prices.
- Opportunities in developing next-generation drugs with extended patents or novel mechanisms to maintain market exclusivity.
Emerging Therapeutic Developments
| Drug Candidate | Stage | Mechanism of Action | Notable Features |
|---|---|---|---|
| ABBV-4083 | Phase II | Anti-Wolbachia | Improved efficacy over doxycycline, shorter treatment duration |
| Emodepside | Preclinical | Ion channel modulator | Broad spectrum, oral bioavailability |
| Oxantel Pamoate | Repurposed | Nicotinic receptor agonist | Effective against various filarial species |
Research Trends
- Increased focus on host-parasite biology to identify novel drug targets.
- Use of genomics and proteomics to develop targeted therapies.
- Exploration of drug repurposing for accelerated development—especially antibiotics and anti-inflammatory agents.
Competitive Landscape and Market Players
| Top Players | Key Focus | Recent Developments | Strategic Moves |
|---|---|---|---|
| Sanofi | Ivermectin formulations, resistance | Patent filings, licensing | Diversification into combination therapies |
| GlaxoSmithKline | Anti-Wolbachia drugs | Lead candidate data release | Partnership with academia |
| Bayer | Macrocyclic lactones | Expansion of pipeline | Mergers, licensing |
| Infectious Disease Research Institute | Biologics, diagnostics | New collaborations | Focus on NTD (Neglected Tropical Diseases) |
New Entrants and Collaborations
- Start-ups in biotech leveraging AI for target identification.
- Academic institutions partnering with industry to fast-track candidate screening.
- Public-private partnerships for demonstration projects (e.g., WHO collaborations).
Regulatory and Policy Considerations
| Region | Regulatory Pathway | Key Policies | Impact |
|---|---|---|---|
| US | FDA Orphan Drug Designation | Orphan Drug Act | Incentives for rare disease drugs |
| EU | PRIME scheme | Streamlined approval process | Accelerates development |
| WHO | Prequalification process | Essential Medicines List | Market access in endemic regions |
Implications for Patent Strategies
- Patent filings aligned with clinical milestones improve exclusivity periods.
- Data exclusivity and orphan provisions can extend effective patent life.
- Regulatory hurdles necessitate strategic patenting in multiple jurisdictions.
Comparison of Filaricide Drugs
| Drug | Type | Mechanism | Approval Year | Patent Status | Key Advantages | Limitations |
|---|---|---|---|---|---|---|
| Ivermectin | Macrocyclic lactone | Glutamate-gated chloride channels | 1987 | Expiring (2024) | Proven safety, effective for onchocerciasis | Resistance concerns, not macrofilaricidal |
| Diethylcarbamazine (DEC) | Organic compound | Unknown, affects microfilariae | 1950s | Generic | Widely used, inexpensive | Not macrofilaricidal, adverse reactions |
| Albendazole | Benzimidazole | Inhibits microtubule synthesis | 1970s | Generic | Broad antiparasitic | Limited macrofilaricidal activity |
| ABBV-4083 | Novel | Anti-Wolbachia | Phase II | Patent pending | Shorter treatment | Still under clinical evaluation |
FAQs
1. How does patent expiration impact drug prices in the filaricide market?
Patent expirations generally lead to generic manufacturing, significantly reducing the price of existing therapies. As key ivermectin patents expire around 2024, a surge in generic options is expected, enhancing affordability for endemic regions.
2. Are there any breakthrough drugs in late-stage development for filarial infections?
Yes. ABBV-4083 is a leading candidate in phase II development, promising shorter courses and improved efficacy against Wolbachia-infected filarial parasites, which could revolutionize treatment protocols.
3. What role do combination therapies play in the market?
Combination therapies aim to improve cure rates, reduce resistance, and simplify treatment regimens. Ongoing research explores pairing existing drugs like ivermectin with new anti-Wolbachia agents and doxycycline derivatives.
4. How does resistance development influence future drug innovation?
Resistance, especially to ivermectin in Loa loa, presents significant challenges. It drives the exploration of novel mechanisms, biologics, and genetically targeted therapies to circumvent resistance pathways.
5. What policies support innovation in neglected tropical disease treatments?
Agencies like the WHO, FDA, and EMA provide incentives such as orphan drug designations, accelerated approval pathways, and prequalification programs, fostering pipeline development for filaricide drugs.
Key Takeaways
- The filaricide market is driven by global health initiatives, with a current valuation of approximately USD 0.7 billion and an anticipated CAGR of 12% through 2028.
- Patent expirations, particularly of ivermectin in 2024, will catalyze generic entry, reducing costs but intensifying competition.
- Advances in drug development focus on anti-Wolbachia agents, combination therapies, and targeted biologics, signaling a shift towards more effective, shorter regimens.
- Patent landscape analysis reveals a shift from traditional macrocyclic lactone formulations toward biologics and novel mechanisms, supported by collaborative research efforts.
- Regulatory incentives are critical in accelerating clinical development and market access, particularly in endemic regions with limited healthcare budgets.
- The landscape remains competitive, with a mix of large pharma, biotech startups, and academia shaping innovation trajectories.
References
[1] WHO. (2021). Global programme to eliminate lymphatic filariasis: progress report.
[2] MarketWatch. (2023). Filaricides Market Size and Forecast.
[3] PatentScope. WIPO. (2023). Patent filings related to filaricides.
[4] GlobalData. (2022). Pipeline Analysis for Filariasis Drugs.
[5] ClinicalTrials.gov. (2023). Current clinical trials for filaricide development.
More… ↓
